Shai Novik is the Executive Chairman of the Board and has been such since 2014.
Mr. Novik previously founded PROLOR Biotech in 2005, and served as its President until 2014. PROLOR Biotech was listed on the NYSE in 2010 and was sold in 2013, in a $560 million transaction. Prior to PROLOR, Mr. Novik served as Chief Operating Officer and Head of Strategic Planning of THCG, Inc., a technology and life sciences investment company. THCG was a portfolio company of Greenwich Street Partners, one of the largest U.S. private equity funds. THCG’s own portfolio included several life sciences and medical devices companies.
Mr. Novik received his M.B.A, with distinction, from Cornell University.